Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Session includes invitee/speaker with CF. Others with CF encouraged to participate virtually.
Session includes invitee/speaker with CF. Others with CF encouraged to participate virtually.

IMI
Workshop

W38--Epidemiology & Management of Infection in CF

Saturday, September 28, 2024
10:15 AM - 12:15 PM ET
Location:257 AB

Recorded Session

This session will highlight novel approaches to treatment of challenging pathogens in cystic fibrosis (CF), particularly Mycobacterium abscessus, Pseudomonas, and Stenotrophomonas. These bacteria often persist despite aggressive antimicrobial therapy and can cause significant decline in lung function. During this session, we will cover novel alternative treatment options, new approaches to predicting treatment response, and the interplay between pathogens in the CF microbiome. We will also hear updates on the clinical management and treatment duration for pulmonary exacerbations.

Learning Objectives:

  • Review novel therapeutic options for challenging CF pathogens.
  • Examine the impact of antimicrobial treatment on co-infections.
  • Discuss ways to improve management of infections in CF patients.

Presentations:

  • 10:15 AM - 12:15 PM ET
    W38.1- Impact of the STOP2 trial on PEx treatment duration at CF Centers across the US

    Speaker: Sonya L. Heltshe, PhD (she/her/hers) – TDNCC & UW

  • 10:15 AM - 12:15 PM ET
    W38.2- Mycobacterium Abscessus Drug Tolerance Assessments Reveal Clinical Outcomes.

    Speaker: Lucas Boeck, MD – University of Basel

  • 10:15 AM - 12:15 PM ET
    W38.3- Antibiotics used to treat Pseudomonas infections may enhance Mycobacterium abscessus persistence in the CF lung

    Speaker: Jodi M. Corley, PhD, MS (she/her/hers) – National Jewish Health

  • 10:15 AM - 12:15 PM ET
    W38.4- Safety and efficacy of nebulized phage in CF patients with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study

    Speaker: Urania Rappo, MD – BiomX Inc

  • 10:15 AM - 12:15 PM ET
    W38.5- Medium chain fatty acids improve bacteriophage killing of Stenotrophomonas maltophilia

    Speaker: Sage J. B Dunham, PhD – UC Irvine